Regulatory26 Jun 2026, 12:37 pm
Marksans Pharma Resubmits Financial Results for FY26
AI Summary
Marksans Pharma Ltd has resubmitted its financial results for the quarter and year ended March 31, 2026, in a machine-readable format after an initial submission on May 26, 2026, was deemed not to be in the required format by the NSE. The company stated that the oversight was unintentional and has assured that such an occurrence will be prevented in the future. The resubmission is in continuation of the 'Outcome of the Board Meeting' filing. The accompanying Independent Auditor's Report from MSKA & Associates LLP confirms that the standalone annual financial results are presented in accordance with SEBI Listing Regulations and provide a true and fair view.
Key Highlights
- Marksans Pharma resubmitted FY26 financial results in machine-readable format.
- Initial submission on May 26, 2026, lacked the required format.
- Company attributes the error to an unintentional oversight.
- Auditor's report confirms compliance with SEBI regulations.
- Measures will be taken to prevent future formatting errors.
Price Impact
More from MARKSANS